| Trial Name | Description |
| HOPE Trial Prostate |
Dr. L. Mendez Is hypofractionated whole-pelvis radiotherapy (WPRT) as well tolerated as conventionally-fractionated WPRT in prostate cancer patients? |
| PCS 6 |
Dr. D'Souza Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI). |
| PCS IX |
Dr. Michael Lock The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial (PCS IX) |
| ARASTEP GU |
Dr. E. Winquist A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer |
| PROTRACT GU |
Dr. E. Winquist Not open yet - PROTRACT (Prostate Cancer Treatment Optimization via Analysis of Circulating Tumour DNA) Study: A Randomized Phase II Trial Comparing Biomarker Directed Therapy versus Clinician's Choice of Enzalutamide or Docetaxel in Patients with Advance |
| IND.223 |
Dr. Eric Winquist A Phase II Study of Palbociclib, A CDK 4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer. |
| Litespark GU |
Dr. E. Winquist A multicenter, double-blind, randomized phase 3 study to compare the efficacy and safety of Belzutifan (MK-6482) plus Pembrolizumab (MK-3475) versus placebo plus Pembrolizumab, in the adjuvant treatment of clear cell renal cell carcinoma p |
| PERFORM Renal |
Dr. R. Fernandes Preventing Immune-Related Adverse Events in Renal Cell Carcinoma Patients Treated with Combination Immunotherapy using Fecal Microbiota Transplantation |
| Renal mTor |
Dr. M. Haeryfar Regulation of T cell responses by inhibitors of mammalian target of rapamycin (mTOR) |
| REaCT-HOLD BMA |
Dr. R Fernanes A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer. (REaCT-Hold BMA) |
| ARGOS/CLIMBER GU |
Dr. Glenn Bauman PSMA MRI Guided Prostate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of Imaging Biomarkers Post Radiotherapy (CLIMBER) |
| IND.234 |
Dr. Eric Winquist Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study. |
| CONTACT-02 GU |
Dr. R. Fernandes A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer |
| TROPICS-04 Bladder |
Dr. R. Fernandes A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer |
| BL.13 |
Dr. Eric Winquist A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients With Muscle-Invasive Bladder Cancer. |
| AQuOS-II (GU) |
Dr. Lucas Mendez Assessment of Quality of Life and Outcomes in Patients Treated with Stereotactic Body Radiotherapy (SBRT) for Primary Renal Cell Carcinoma (RCC): AQuOS-II |
| EMT Prostate |
Dr. Alison Allan Dynamic influence of the epithelial-to-mesenchymal transition (EMT) on circulating tumor cell (CTC) generation, phenotype, and disease progression in prostate cancer. |
| PEACE III GU |
Dr. E. Winquist A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone |
| ALPACA Penile |
Dr. E. Winquist A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy |
| CYTOSHRINK GU |
Dr. Eric Winquist Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer. |
| EV-302 GU |
Dr. Ricardo Fernandes An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer. |
| MOUNTAINEER-02 |
Dr. D. Breadner A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2 |
| RADIANT Bladder |
Dr. R. Fernandes Neoadjuvant Immune-Modulating Radiation with Durvalumab (MEDI4736) prior to Radical Cystectomy in Patients with Muscle-Invasive Bladder Carcinoma |
| PR.19 |
Dr. Joelle Helou A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. |
| EvoPAR-Prostate01 |
Dr. R. Fernandes A Randomized, 2-Cohort, Double-blind, Placebo-Controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer |
| CYTOSHRINK Renal |
Dr. E. Winquist Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer |